Sami Labs adds 4 US patents to its IP portfolio


Sami Labs, Bangalore based multinational health-science company added to its very long track record of innovative Intellectual Property‬ development with four new US patents, bringing the company’s patent portfolio total to 98.

These most recent patents include:

– US Patent 8383594 was accorded to the invention titled “‎Peptides‬ modified with triterpenoids and small organic molecules: synthesis and use in ‎cosmeceuticals‬”. OLEPENT® has been shown by extensive research to be stable and capable of delivering the active principles right into the target areas of the skin with profound beneficial effects on aspect of skin aging.

– US Patent 8394852 is for the invention titled “Inotilone derivatives as coherent biological response modifier (cBMR)”. The invention discloses a new composition of matter, an inotilone analog, and also its ability to modulate biological responses.

– US Patent 8853407, a process patent for the synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal. The invention is for a shorter, practical, scalable synthetic method for the synthesis of the 4-aryl 1, 4-diacyl dihydropyridine group of compounds. The extensive applications of 4-aryl 4-acyl ‪‎piperidine‬ in the fields of investigation drugs and medicinal chemistry are well known. The earlier known synthetic methods involved lengthy processes, use of hazardous chemicals and non-scalability at industrial levels. The SAMI-SABINSA process overcomes all the technical challenges by using favorable starting materials and metallic indium as a catalyst in a safe synthetic process.‬

– US Patent 8987212: Sabinsa’s triterpenoid peptide product OLEPENT® received its second US patent, which claims ‪#‎therapeutic‬ efficacy in effectively reducing skin wrinkling through anti-elastase activity. The signal peptide technology disclosed in this patent demonstrates an effective therapeutic means to counter the ill effects of serine protease enzymes on the human skin.‬

“Today the main thrust and focus of Sami Labs is on new product development and market oriented research,” said Dr. Muhammed Majeed, founder and chairman, Sami Labs.

Over the past 25 years, Sabinsa Corporation, an arm of the Sami Labs based in the USA has brought to market more than 100 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 110 full time scientists conducting ongoing research in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market.

Read Previous

Competitive situation is complex in India: Christian Philippsen, Managing Director BENEO Asia

Read Next

’Demands for healthy and functional food is expected to grow’

Leave a Reply